Products for Research Use Only

Dolutegravir (sodium)

CAT: 0804-HY-13238A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13238A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) [1][2].
CAS Number
1051375-19-9
Product Name Alternative
S/GSK1349572 (sodium)
UNSPSC
12352005
Hazard Statement
H400, H410
Target
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Dolutegravir-sodium.html
Purity
99.97
Solubility
DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
O=C(C1=CN(C2=C(O[Na])C1=O)C[C@]3([H])OCC[C@@H](C)N3C2=O)NCC4=CC=C(F)C=C4F
Molecular Formula
C20H18F2N3NaO5
Molecular Weight
441.36
Precautions
H400, H410
References & Citations
[1]Kobayashi M, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011 Feb;55 (2) :813-21.|[2]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) . Mol Pharmacol. 2011 Oct;80 (4) :565-72.|[3]Moss L, et al. The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. Xenobiotica. 2015 Jan;45 (1) :60-70.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1
Citation 01
Antiviral Res. 2025 Sep 11:106283.|Biomed Pharmacother. 2025 Nov 28:193:118831.|Anal Bioanal Chem. 2018 Nov;410 (29) :7773-7781. |Antivir Ther. 2017;22 (8) :645-657. |Biochem Biophys Res Commun. 2017 Jul 1;488 (3) :433-438.|Biochem Pharmacol. 2024 Feb:220:116010.|bioRxiv. 2025 May 18.|Cell Physiol Biochem. 2016 Jul 21;39 (2) :639-650.|Cell Rep Med. 2024 Aug 26:101702.|Cell Rep Med. 2024 Jul 2:101643.|Cell. 2025 Sep 4;188 (18) :4896-4912.e19.|Drug Metab Dispos. 2019 Jul;47 (7) :768-778. |Drug Metab Dispos. 2019 May;47 (5) :535-544. |FASEB J. 2025 Feb 28;39 (4) :e70377.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|J Clin Pharmacol. 2019 Sep;59 Suppl 1:S42-S55.|J Infect Dis. 2022 Nov 28;226 (11) :1992-2001.|J Neuroimmune Pharmacol. 2021 Mar;16 (1) :159-168.|Life Sci. 2022 Nov 1:308:120948.|Open Forum Infect Dis. 2024 Nov 29;12 (1) :ofae705.|PeerJ Physical Chemistry. 2019, 1:e6.|Pharmaceuticals (Basel) . 2022 Feb 18;15 (2) :242.|PLoS One. 2020 Jan 23;15 (1) :e0226924. |Preprints. 2024 Apr 23.|Res Sq. 2024 May 24.|Sci Adv. 2025 Sep 12;11 (37) :eadz8980. |Science. 2020 Feb 14;367 (6479) :806-810. |Toxicol Appl Pharmacol. 2019 Apr 1:368:18-25.|Viruses. 2021 Jan 18;13 (1) :131.|Viruses. 2024 Oct 13;16 (10) :1607.